Under an agreement, ProBioGen will develop a stable cell-line for and manufacture an anti-cancer antibody for Chiome using its proprietary cancer cell-killing technology.
ProBioGen, a service and technology provider for complex therapeutic glycoproteins, announced on Oct. 5, 2017 that it signed a service and license agreement with Chiome Bioscience, a Japanese antibody discovery and development company, to use ProBioGen’s cancer cell-killing technology, GlymaxX, for a clinical candidate in an antibody manufacturing program for Chiome.
Specifically, ProBioGen will develop a stable GlymaxX cell line and then will conduct process development and GMP manufacturing of the antibody, which is derived from antibody-dependent cell-mediated cytotoxicity (ADCC)-enhanced cancer stem cells. The antibody will be optimized for cancer cell-killing activity.
Dr. Koji Nakamura, head of drug discovery laboratories and former CEO of LivTech, an R&D and antibody drug discovery company acquired by Chiome in December 2013, explained in a company press release: “We have tested ProBioGen’s GlymaxX technology for our antibody before and saw in-vivo in animal models an obviously potentiated cancer cell-killing efficacy of its afucosylated version. This, together with our long-standing relationship with the ProBioGen team, the company’s demonstrated track record in developing stable cell lines up to reliable GMP manufacturing for small and big biotechs, and the favorable, royalty-free commercial GlymaxX Terms, made our selection quite simple.”
“We look much forward to a productive partnership which combines Chiome’s outstanding antibody drug candidate, LIV-1205, with our own antibody development expertise and our GlymaxX ADCC enhancement technology to make together with Chiome a marked contribution to combat various cancers,” said ProBioGen’s CEO Wieland Wolf in the release.
Source: ProBioGen
INTERPHEX 2025: Critical Role of Walk-In Chambers in Bio/Pharma Development and Manufacturing
April 3rd 2025Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, sat down with the PharmTech Group at INTERPHEX 2025 to discuss the design and critical role of walk-in chambers in the bio/pharmaceutical industry.
AES Clean Technology Launches Next-Generation OSM Utility Solution for Cleanrooms at INTERPHEX 2025
April 2nd 2025Officially launched at INTERPHEX 2025, the Omni ASCENT is a next-generation off-site manufactured vertical utility solution that offers optimized cleanroom flexibility and efficiency.